SCHEMBL6025644

SCHEMBL6025644

Cc1ccc(-c2nc(C(=O)O)ncc2-c2ccc(Cl)cc2)c(C)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ KDM4E B2RXH2 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ PTGDR2 Q9Y5Y4 1/20 0.52
▸ DHODH Q02127 5/20 0.44
▸ KMO O15229 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ AHR P35869 1/20 0.43
▸ GRM2 Q14416 1/20 0.41
▸ MAP4K4 O95819 2/20 0.40
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ABL1 P00519 1/20 0.38
▸ MT-CO1 P00395 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4807383 0.82 CNR1 (0.53) KMOCNR2
SCHEMBL6025473 0.72 CNR1 (0.51) CNR2
SCHEMBL14850871 0.72 KMT2A (0.46) MEN1KMT2AKDM4EALDH1A1PTGDR2
SCHEMBL6025849 0.72 KMO (0.47) MEN1KMT2AKDM4EALDH1A1DHODH
SCHEMBL25210699 0.71 KMO (0.55) KDM4EDHODHKMOLMNA
SCHEMBL25252045 0.71 KDM4E (0.45) MEN1KMT2AKDM4EALDH1A1KMO
SCHEMBL25245579 0.71 KMO (0.46) DHODHKMONPC1RAB9AGRM2
SCHEMBL25208397 0.70 DHODH (0.44) DHODHKMOGRM2MT-CO1CCKAR
SCHEMBL18952684 0.70 KMT2A (0.43) MEN1KMT2AKDM4EALDH1A1PTGDR2
SCHEMBL32680061 0.70 DHODH (0.44) DHODHKMOGRM2MT-CO1CCKAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-12-23 — — US claimed
EP-1638570-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2006-03-29 — — EP disclosed
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-12-23 — — US disclosed
WO-2004110453-A1 PYRIMIDINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2004-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259887-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 MEN1 4394/4885KMT2A 3816/4885KDM4E 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback